Brief: Acrux Says Us FDA Accepted For Review Co's Abbreviated New Drug Application
12/09/2021 23:27
Sept 13 (Reuters) - Acrux Ltd ACR.AX :
* US FOOD AND DRUG ADMINISTRATION HAS ACCEPTED FOR REVIEW
CO'S
ABBREVIATED NEW DRUG APPLICATION FOR ITS GENERIC VERSION OF
DAPSONE GEL, 5%
Source text for Eikon: ID:nASXvtvrV
Further company coverage: ACR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acrux
See all newsBrief: Acrux Licenses Lenzetto For Australian Market For A$5.4 Million
Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
Brief: Acrux Says Capital Gains Tax Exemptions Remain In Place For Acrux
Australia's Acrux jumps on placement to fund female testosterone program
Brief: Acrux Raises A$1.6 Mln Via At 0.95 AU Cents Per Share